Validation study of the Vitiligo Extent Score-plus
To the Editor: The Vitiligo Extent Score (VES) is a reliable instrument to assess the extent of vitiligo. 1 However, international vitiligo experts expressed concerns that the pictures included in the VES do not show a perifollicular repigmentation pattern similar to that in the Vitiligo Area Scoring Index. 2, 3 On the basis of this concern, an additional perifollicular scale was added to the VES (named the VESplus). In this research letter we have assessed the validity and reliability of the VESplus as a static score. 4 In another study, we have reported the responsiveness of the VESplus. 5 VES and VESplus measurements on baseline pictures of 57 patients who were receiving topical therapy (group 1, 3 raters) or ultraviolet B therapy (group 2, 2 raters) were performed independently (a subanalysis on follicular repigmentation was performed on follow-up pictures). Approval by ethics committees was obtained. Validity of VESplus. Overall, VES and VESplus were highly correlated both for total body surface area (BSA) (r ¼ 0.984, P \.001) (Fig 1) and regional assessment (r ¼ 0.962, P \.001). Wilcoxon analysis showed no significant difference in estimation of BSA between the 2 methods. Bland-Altman plots showed that the 2 methods could be used interchangeably (data not shown). Regional analysis showed a similar correlation between VES and 
VESplus in regions with
In groups 1 and 2, the inter-rater agreements for total body and regional evaluation were excellent for VES and VESplus (Table I ). In both group 1 and group 2, the intrarater reliability was comparable for VES ( group 1: ICC, 0.958 and 95% confidence interval [CI], 0.936-0.972; group 2: ICC, 0.980 and 95% CI, 0.967-0.988) and VESplus ( group 1: ICC, 0.937 and 95% CI, 0.905-0.959; group 2: ICC, 0.981; 95% CI, 0.967-0.989). SDCs were around 1% (Table I) .
The mean times for using VESplus and VES was 67.0 s/patient and 71.1 s/patient, respectively. The mean satisfaction scores for VESplus and VES were 3.4 out of 5 and 4.2 out of 5 respectively.
In this study we found that the VESplus is a valid, reliable, and user-friendly instrument to determine the extent of vitiligo. We observed no systematic differences between VES and VESplus in this study population (mean BSA, \5% in 93% of cases). Given the finding that the SDC for both methods is similar but the VESplus might more often detect very small differences (responsiveness study), additional studies are necessary to make final statements on the added value of the perifollicular repigmentation scale. These studies should focus on patients with perifollicular repigmentation, vitiligo of variable extent, and darker skin types, and they should preferably include a comparison with the Vitiligo Area Scoring Index.
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To the Editor: Patients with vitiligo often have unpredictable, fluctuating periods of inactivity interspersed with periods of depigmentation. 1 The Vitiligo Disease Activity Index (VIDA) is an outcome measure used to determine disease activity in patients with vitiligo.
2 Unlike other disease activity scores in dermatology, the VIDA relies on patient recall. Although clinical signs of active disease such as confetti-like depigmentation, Koebner phenomenon, and trichrome depigmentation are predictors of disease activity, there is no activity score that incorporates these findings. [3] [4] [5] The VIDA score asks the patient to recall the last time they noted depigmentation during the past 12 months using a 6-point scale from e1 to 14, with higher scores indicating more recent disease activity. Our objective was to determine if patients are capable of accurately recalling their disease activity using the VIDA score.
We performed a retrospective, case-control study of VIDA scores for patients with vitiligo obtained at baseline and a follow-up visit 6 weeks to 6 months later. We used the temporal restrictions of the chosen VIDA scores and the clinician-derived Vitiligo Area Scoring Index (VASI) score as a method to determine the accuracy of the patient's VIDA score. The VASI score is used to determine the severity of depigmentation in patients with vitiligo. 6 Predetermined, written rules outlined the requirements for scores that were either consistent or inconsistent with the temporal window of the patient's chosen VIDA score and clinician-performed assessment of pigmentation (Table I) . These rules were applied to each follow-up VIDA score to determine whether the score was accurate. Inclusion criteria required a VIDA and VASI score documented at baseline and follow-up 6 weeks to 6 months later for subjects enrolled in the Dallas Vitiligo Registry at the University of Texas Southwestern Medical Center.
A total of 43 follow-up VIDA scores met inclusion criteria and were analyzed. A one-sample proportions test with a Yates correction for continuity was used to test the null hypothesis, which showed that the proportion of accurate follow-up VIDA scores was no different than that which would occur by chance. There were a total of 25 accurate scores and 19 inaccurate scores (58% scores correct). Our study failed to reject the null hypothesis that the percentage of accurate scores is no different from that which would occur by chance, ie, a patient's chance of accurately
